Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 601

1.

Effect of orlistat on weight regain and cardiovascular risk factors following a very-low-energy diet in abdominally obese patients: a 3-year randomized, placebo-controlled study.

Richelsen B, Tonstad S, Rössner S, Toubro S, Niskanen L, Madsbad S, Mustajoki P, Rissanen A.

Diabetes Care. 2007 Jan;30(1):27-32.

PMID:
17192328
2.

X-PERT: weight reduction with orlistat in obese subjects receiving a mildly or moderately reduced-energy diet: early response to treatment predicts weight maintenance.

Toplak H, Ziegler O, Keller U, Hamann A, Godin C, Wittert G, Zanella MT, Zúñiga-Guajardo S, Van Gaal L.

Diabetes Obes Metab. 2005 Nov;7(6):699-708.

PMID:
16219013
3.

Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.

Halpern A, Mancini MC, Suplicy H, Zanella MT, Repetto G, Gross J, Jadzinsky M, Barranco J, Aschner P, Ramirez L, Matos AG.

Diabetes Obes Metab. 2003 May;5(3):180-8.

PMID:
12681025
4.

Orlistat in the treatment of overweight or obese Chinese patients with newly diagnosed Type 2 diabetes.

Shi YF, Pan CY, Hill J, Gao Y.

Diabet Med. 2005 Dec;22(12):1737-43.

PMID:
16401321
6.

[Randomized placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients].

Sjostrom L, Rissanen A, Andersen T, Boldrin M, Golay A, Koppeschaar H, Krempf M; European Multicenter Orlistat Study Group.

Ter Arkh. 2000;72(8):50-4. Russian.

PMID:
11019429
7.

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study.

Hollander PA, Elbein SC, Hirsch IB, Kelley D, McGill J, Taylor T, Weiss SR, Crockett SE, Kaplan RA, Comstock J, Lucas CP, Lodewick PA, Canovatchel W, Chung J, Hauptman J.

Diabetes Care. 1998 Aug;21(8):1288-94.

PMID:
9702435
8.
9.

XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients.

Torgerson JS, Hauptman J, Boldrin MN, Sjöström L.

Diabetes Care. 2004 Jan;27(1):155-61. Erratum in: Diabetes Care. 2004 Mar;27(3):856.

PMID:
14693982
10.

Effects of weight loss with orlistat on glucose tolerance and progression to type 2 diabetes in obese adults.

Heymsfield SB, Segal KR, Hauptman J, Lucas CP, Boldrin MN, Rissanen A, Wilding JP, Sjöström L.

Arch Intern Med. 2000 May 8;160(9):1321-6.

PMID:
10809036
11.

Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin.

Miles JM, Leiter L, Hollander P, Wadden T, Anderson JW, Doyle M, Foreyt J, Aronne L, Klein S.

Diabetes Care. 2002 Jul;25(7):1123-8. Erratum in: Diabetes Care. 2002 Sep;25(9):1671..

PMID:
12087008
13.

Effect of orlistat on cardiovascular disease risk in obese adults.

Swinburn BA, Carey D, Hills AP, Hooper M, Marks S, Proietto J, Strauss BJ, Sullivan D, Welborn TA, Caterson ID.

Diabetes Obes Metab. 2005 May;7(3):254-62.

PMID:
15811142
15.

The long-term influence of orlistat on dietary intake in obese subjects with components of metabolic syndrome.

Svendsen M, Helgeland M, Tonstad S.

J Hum Nutr Diet. 2009 Feb;22(1):55-63. doi: 10.1111/j.1365-277X.2008.00920.x.

PMID:
19192027
16.

Orlistat in hypertensive overweight/obese patients: results of a randomized clinical trial.

Bloch KV, Salles GF, Muxfeldt ES, Da Rocha Nogueira A.

J Hypertens. 2003 Nov;21(11):2159-65.

PMID:
14597860
17.

Orlistat, sibutramine, or combination therapy: which performs better on waist circumference in relation with body mass index in obese patients?

Aydin N, Topsever P, Kaya A, Karasakal M, Duman C, Dağar A.

Tohoku J Exp Med. 2004 Mar;202(3):173-80.

19.

The effect of orlistat-induced weight loss, without concomitant hypocaloric diet, on cardiovascular risk factors and insulin sensitivity in young obese Chinese subjects with or without type 2 diabetes.

Tong PC, Lee ZS, Sea MM, Chow CC, Ko GT, Chan WB, So WY, Ma RC, Ozaki R, Woo J, Cockram CS, Chan JC.

Arch Intern Med. 2002 Nov 25;162(21):2428-35.

PMID:
12437401
20.

Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss.

Jacob S, Rabbia M, Meier MK, Hauptman J.

Diabetes Obes Metab. 2009 Apr;11(4):361-71. doi: 10.1111/j.1463-1326.2008.00970.x. Epub 2009 Jan 22.

PMID:
19207292

Supplemental Content

Support Center